Literature DB >> 20700701

TIM-3 and its regulatory role in immune responses.

Chen Zhu1, Ana C Anderson, Vijay K Kuchroo.   

Abstract

T cell immunoglobulin mucin-(TIM)-3 was first identified as a molecule specifically expressed on IFN-γ-secreting CD4(+) T helper 1 (Th1) and CD8(+) T cytotoxic (Tc1) cells in both mice and humans. TIM-3 acts as a negative regulator of Th1/Tc1 cell function by triggering cell death upon interaction with its ligand, galectin-9. This negative regulatory function of TIM-3 has now been expanded to include its involvement in establishing and/or maintaining a state of T cell dysfunction or "exhaustion" observed in chronic viral diseases. In addition, it is now appreciated that TIM-3 has other ligands and is expressed on other cell types, where it may function differently. Given that an increasing body of data support an important role for TIM-3 in both autoimmune and chronic inflammatory diseases in humans, deciphering the function of TIM-3 on different cell types during different immune conditions and how these can be regulated will be critical for harnessing the therapeutic potential of TIM-3 for the treatment of disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20700701     DOI: 10.1007/82_2010_84

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  62 in total

Review 1.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

3.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Authors:  Gulidanna Shayan; Raghvendra Srivastava; Jing Li; Nicole Schmitt; Lawrence P Kane; Robert L Ferris
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

4.  Expression of Tim-1 and Tim-3 in Plasmodium berghei ANKA infection.

Authors:  Bo Huang; Man Liu; Shiguang Huang; Bin Wu; Hong Guo; Xin-Zhuan Su; Fangli Lu
Journal:  Parasitol Res       Date:  2013-05-08       Impact factor: 2.289

Review 5.  Role of Tim-3 in hepatitis B virus infection: An overview.

Authors:  Yuan Liu; Li-Fen Gao; Xiao-Hong Liang; Chun-Hong Ma
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 6.  Immunomodulatory therapy for melanoma: ipilimumab and beyond.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

Review 7.  Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.

Authors:  Jianbiao Zhou; Wee-Joo Chng
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

8.  Increased Gal-9 and Tim-3 expressions during liver damage in a murine malarial model.

Authors:  Siyu Xiao; Jinfeng Liu; Shiguang Huang; Fangli Lu
Journal:  Parasitol Res       Date:  2016-02       Impact factor: 2.289

9.  T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer.

Authors:  Danian Tong; Yujia Zhou; Wei Chen; Yang Deng; Lei Li; Zhenyi Jia; Dachuan Qi
Journal:  Mol Biol Rep       Date:  2012-06-26       Impact factor: 2.316

10.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.